Point Gets Edge Over Acusphere With CardioSphere NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The myocardial perfusion imaging agent for use with ultrasound has a user fee date in late October, firm says.
You may also be interested in...
Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up
Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.
Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up
Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.
CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.